IN2014KN02929A - - Google Patents

Info

Publication number
IN2014KN02929A
IN2014KN02929A IN2929KON2014A IN2014KN02929A IN 2014KN02929 A IN2014KN02929 A IN 2014KN02929A IN 2929KON2014 A IN2929KON2014 A IN 2929KON2014A IN 2014KN02929 A IN2014KN02929 A IN 2014KN02929A
Authority
IN
India
Prior art keywords
complex
complexes
hcmv
disclosure
ul131a
Prior art date
Application number
Other languages
English (en)
Inventor
Andrea Carfi
Yingxia Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48783208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN02929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014KN02929A publication Critical patent/IN2014KN02929A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2929KON2014 2012-07-06 2013-06-29 IN2014KN02929A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668975P 2012-07-06 2012-07-06
US201361770257P 2013-02-27 2013-02-27
PCT/EP2013/063750 WO2014005959A1 (fr) 2012-07-06 2013-06-29 Complexes de protéines de cytomégalovirus

Publications (1)

Publication Number Publication Date
IN2014KN02929A true IN2014KN02929A (fr) 2015-05-08

Family

ID=48783208

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2929KON2014 IN2014KN02929A (fr) 2012-07-06 2013-06-29

Country Status (17)

Country Link
US (4) US9683022B2 (fr)
EP (1) EP2869843B1 (fr)
JP (3) JP2015522581A (fr)
KR (1) KR20150031322A (fr)
CN (1) CN104853771A (fr)
AU (1) AU2013286093B2 (fr)
CA (1) CA2878344A1 (fr)
ES (1) ES2753138T3 (fr)
GB (1) GB2513768B (fr)
HK (1) HK1210037A1 (fr)
IL (1) IL236261A0 (fr)
IN (1) IN2014KN02929A (fr)
MX (2) MX355469B (fr)
RU (1) RU2015103891A (fr)
SG (1) SG11201408328VA (fr)
WO (1) WO2014005959A1 (fr)
ZA (1) ZA201409364B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878344A1 (fr) 2012-07-06 2014-01-09 Novartis Ag Complexes de proteines de cytomegalovirus
CN110241137A (zh) 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
WO2015165480A1 (fr) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Compositions de vaccin de cytomégalovirus humain et leur procédé de production
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3015475A1 (fr) 2014-10-31 2016-05-04 Novartis AG Cellules de mammifère exprimant des antigènes du cytomégalovirus
EP3048114A1 (fr) 2015-01-22 2016-07-27 Novartis AG Antigènes du cytomégalovirus et leurs utilisations
EP3047856A1 (fr) * 2015-01-23 2016-07-27 Novartis AG Antigènes de cytomégalovirus (cmv) et leurs utilisations
WO2017044895A2 (fr) 2015-09-10 2017-03-16 City Of Hope Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
BR112018014109A2 (en) 2016-01-11 2018-12-11 Verndari, Inc. microneedle compositions and methods of using them
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (fr) 2016-10-21 2020-07-01 ModernaTX, Inc. Vaccin contre le cytomégalovirus humain
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CA3060019A1 (fr) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Proteines de cytomegalovirus modifiees et complexes stabilises
US11174322B2 (en) * 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CN111163799A (zh) 2017-07-28 2020-05-15 扬森疫苗与预防公司 用于异源repRNA免疫接种的方法和组合物
US11524069B2 (en) * 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019169120A1 (fr) 2018-02-28 2019-09-06 University Of Washington Vaccins à base de nanostructures auto-assemblables
CN112638411B (zh) 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
CN113271968B (zh) * 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
CA3121915C (fr) 2018-12-10 2025-05-20 Km Biologics Co., Ltd. Vaccin pour la prévention ou le traitement d'une infection congénitale par le cytomégalovirus
US11629172B2 (en) * 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2021014385A1 (fr) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
CN115698298A (zh) 2020-06-09 2023-02-03 Km生物医薬股份公司 巨细胞病毒的gB与五聚体的融合蛋白和包含该融合蛋白的疫苗
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CA3211449A1 (fr) * 2021-02-24 2022-09-01 Pfizer Inc. Nouvelles regions de cible biologique dans le polypeptide de glycoproteine b du cytomegalovirus humain et leurs procedes d'utilisation
WO2023144665A1 (fr) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006953A2 (fr) 1988-12-22 1990-06-28 Genentech, Inc. Procede de preparation de polypeptides solubles dans l'eau
EP0388186A1 (fr) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company Régulation externe de l'expression de gènes
WO1992002628A1 (fr) 1990-08-02 1992-02-20 Chiron Corporation Expression de glycoproteine-h de cytomegalovirus humain utilisant le systeme d'expression cellulaire de baculovirus-insectes
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5815900A (en) 1995-03-06 1998-10-06 Matsushita Electric Industrial Co., Ltd. Method of manufacturing a surface acoustic wave module
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
EP3031469B1 (fr) 2006-06-07 2023-08-23 The Trustees Of Princeton University Complexe de protéine de surface du cytomégalovirus destiné à être utilisé dans des vaccins et en tant que cible de médicament
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
WO2011027222A2 (fr) 2009-09-02 2011-03-10 Novartis Ag Compositions immunogènes comprenant des modulateurs de l'activité tlr
WO2011106607A2 (fr) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Vaccins à virus fractionné pour les herpesvirus et procédés d'utilisation
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012015211A2 (fr) 2010-07-30 2012-02-02 주식회사종근당 Composition de gouttes ophtalmiques contenant de la cyclosporine a
EP2614072A4 (fr) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth Vaccin à cytomégalovirus humain
WO2012051211A2 (fr) 2010-10-11 2012-04-19 Novartis Ag Plateformes de délivrance d'antigènes
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
MX350258B (es) * 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
MX366055B (es) * 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2878344A1 (fr) 2012-07-06 2014-01-09 Novartis Ag Complexes de proteines de cytomegalovirus
EP3015475A1 (fr) 2014-10-31 2016-05-04 Novartis AG Cellules de mammifère exprimant des antigènes du cytomégalovirus

Also Published As

Publication number Publication date
MX355469B (es) 2018-04-19
GB2513768B (en) 2015-04-15
US9683022B2 (en) 2017-06-20
US20160159864A1 (en) 2016-06-09
US20170320916A1 (en) 2017-11-09
WO2014005959A1 (fr) 2014-01-09
KR20150031322A (ko) 2015-03-23
SG11201408328VA (en) 2015-02-27
ES2753138T3 (es) 2020-04-07
EP2869843A1 (fr) 2015-05-13
US10287322B2 (en) 2019-05-14
JP2015522581A (ja) 2015-08-06
JP2017192399A (ja) 2017-10-26
RU2015103891A (ru) 2016-08-27
CN104853771A (zh) 2015-08-19
US20190211064A1 (en) 2019-07-11
CA2878344A1 (fr) 2014-01-09
EP2869843B1 (fr) 2019-08-07
MX2014015496A (es) 2015-03-06
MX378747B (es) 2025-03-10
GB2513768A (en) 2014-11-05
GB201413863D0 (en) 2014-09-17
AU2013286093B2 (en) 2018-01-04
US20220106364A1 (en) 2022-04-07
JP2017192400A (ja) 2017-10-26
HK1210037A1 (en) 2016-04-15
ZA201409364B (en) 2017-08-30
AU2013286093A1 (en) 2015-02-12
IL236261A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
IN2014KN02929A (fr)
WO2011152566A3 (fr) Composition pour induire une prolifération ou une accumulation de lymphocytes t régulateurs
TN2014000438A1 (en) Anti-fcrn antibodies
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IN2012DN01920A (fr)
MY156697A (en) Modified tuberculosis antigens
WO2016046234A3 (fr) Protéines recombinées sans phe destinées à être utilisées dans le traitement de la phénylcétonurie
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
MY170720A (en) Antibody formulations
HK1211981A1 (en) Methods to control protein heterogeneity
EP3079718A4 (fr) Glycoprotéine b trimère d'herpèsvirus humain, complexes protéiques comprenant gb trimère et leur utilisation comme vaccins
EP4306174A3 (fr) Composition pour stimulation ovarienne contrôlée
PH12016502220A1 (en) Means and methods for treating cmv
PH12016500753A1 (en) Antibodies specific to fcrn
EP2970942A4 (fr) Expression d'acide polysialique, d'antigènes des groupes sanguins, et de glycoprotéine
MX2013008046A (es) Hidrogeles a base de esteres de acido poliisobutenosuccinico.
WO2012047267A3 (fr) Immunogène polyvalent
IN2013MN00733A (fr)
WO2012139106A3 (fr) Virus de l'herpès simplex
MX2012012489A (es) Preparacion de polipeptidos y sales de los mismos.
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций
HK1230070A1 (en) Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
UA102209C2 (ru) Гель для размягчения рубцов с водорастворимым белково-полисахаридных комплексом pleurotus ostreatus
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos